Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nevirapine
Drug ID BADD_D01557
Description A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Indications and Usage For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Marketing Status approved
ATC Code J05AG01
DrugBank ID DB00238
KEGG ID D00435
MeSH ID D019829
PubChem ID 4463
TTD Drug ID D0O2EM
NDC Product Code 53104-7546; 70159-002; 65862-027; 0378-4050; 64380-709; 65862-932; 65862-933; 31722-505; 65862-057; 68554-0044; 33342-004; 0597-0047; 64220-102; 0378-4890; 65162-209; 33342-238; 42571-131
UNII 99DK7FVK1H
Synonyms Nevirapine | Nevirapine Hemihydrate | Hemihydrate, Nevirapine | Viramune | BI-RG-587 | BI RG 587 | BIRG587
Chemical Information
Molecular Formula C15H14N4O
CAS Registry Number 129618-40-2
SMILES CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neutropenia01.02.03.004--Not Available
Neutrophil count13.01.06.046--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oligohydramnios18.05.01.0010.002652%Not Available
Opportunistic infection11.01.08.007--Not Available
Osteonecrosis24.04.05.004; 15.02.04.0070.003978%
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pancreatitis acute07.18.01.0020.003978%Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Peripheral sensory neuropathy17.09.03.0050.003978%
Photophobia06.01.01.004; 17.17.02.0060.002652%
Platelet count13.01.04.011--Not Available
Premature baby18.04.02.0010.005304%Not Available
Pruritus23.03.12.001--
Pyrexia08.05.02.0030.015912%
Rash23.03.13.0010.013791%Not Available
Rash erythematous23.03.13.029--Not Available
Rash maculo-papular23.03.13.0040.002652%
Rash papular23.03.13.017--Not Available
Renal failure20.01.03.0050.007956%Not Available
Respiratory distress22.02.01.0120.002652%Not Available
Rhabdomyolysis15.05.05.002--
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.0050.009282%
Stillbirth18.01.02.002; 08.04.01.0060.003978%Not Available
Surgery25.01.02.003--Not Available
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.0180.005834%Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene